Summary of the studies included in the SLR
| Author | Condition | Study design | Type of intervention/Adherence assessment | Result |
| RA91 patients | RCT, 6 months |
| At 6 months, 85% of the IG compared with 55% of the CG were taking their medication as prescribed (p<0.05) | |
| RA122 patients | RCT, 6 months |
| At 6 months, 98% of the IG were adherent compared with 83% in the CG (p=0.0003) | |
| Multiple chronic diseases including RA 379 patients | RCT, 1 month |
| At 1 month, 91% of the IG were adherent compared with 84% in the CG (p=0.032) | |
| SLE114 patients | RCT, 20 months |
| At 20 months, mean adherence score was 15.6 in the IG compared with 7.7 in the CG (p=0.033) | |
| RA55 patients | RCT, 12 months |
| No significant difference between IG and CG | |
| RA77 patients | RCT, 12 months |
| No significant difference between IG and CG | |
| RA108 patients | RCT, 1 month |
| No significant difference between IG and CG | |
| RA and PsA62 patients | RCT |
| No significant difference between the two types of educational interventions | |
| RA732 patients | Longitudinal cohort study, 6 months |
| At 6 months, mean PDC was 89% in the IG compared with 60% in the CG (p<0.001) | |
| Gout45 patients | Single arm prospective non-controlled study, 12 months |
| Morisky scores improved from median baseline score at 6 months and minimally further increased at 12 months | |
| RA105 patients | Non-randomised controlled study, 5 months |
| No significant difference between website users and non users | |
| SLE41 patients | RCT, 14 months |
| No significant difference between IG and CG | |
| RA201 patients | Prospective cohort study |
| Use of reminders was associated with better adhesion especially in situations at high risk to forget the treatment | |
| RA59 patients | RCT, 12 months |
| At 12 months, significative increase in medication adherence in IG (p<0.05 baseline vs M12)Trend to decrease in medication adherence in CG (p=0.08) | |
| RA234 patients | RCT, 12 months |
| No significant difference between IG and CG | |
| RA18 patients | RCT, 3 months |
| No significant difference between IG and CG | |
| RA and SLE59 patients | Non-randomised, non-controlled study, 6 months |
| At 6 months, there were no significant change in MMAS-8 | |
| SLE714 patients | Prospective non-controlled cohort study |
| Proportion of patients with HCQ blood levels > 500 ng/mL increased from 56% at baseline to 80% in patients who had 3 or more visits | |
| RA166 patients | RCT, 6 months |
| No significant difference between IG and CG | |
| RA, PsA and chronic inflammatory bowel diseases 306 patients | Cohort study, 6 months |
| At 6 months, mean MMAS-4 was 0.17 in IG vs 0.41 in CG (p=0.001) | |
| RA and SpA123 patients | Non-randomised study, 24 months |
| No significant difference between IG and CG | |
| Van den Bemt et al 201140 | RA50 patients | Prospective cohort study |
| Making the rheumatologist aware of patients’ non-adherence did not improve medication adherence |
CG, control group; CQR, Compliance Questionnaire Rheumatology; HCQ, hydroxychloroquine; IG, intervention group; MARS, Medication Adherence Report Scale; MAQ, Medication Adhesion Questionnaire; MMAS, Morisky Medication Adherence Scale; PDC, proportion of days covered; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RCT, randomised controlled trial; SLE, systemic lupus erythematosus; SLR, systematic literature review; SpA, spondyloarthritis .